Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer

Cancer Letters

Volumn 349, Issue 2, 2014, Pages 128-135

  Shi, Hailong ^a   Jiang, Jinling ^a   Ji, Jun ^a   Shi, Min ^a   Cai, Qu ^a   Chen, Xuehua ^a   Yu, Yingyan ^a   Liu, Bingya ^a   Zhu, Zhenggang ^a   Zhang, Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Anti angiogenesis; Capecitabine; Colorectal cancer; CTX; Metronomic chemotherapy

Indexed keywords

CAPECITABINE; FLUOROURACIL; THROMBOSPONDIN 1; VASCULOTROPIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METRONOMIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CYCLE; COLONIC NEOPLASMS; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG SCREENING; HCT116 CELL LINE; HT 29 CELL LINE; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ADMINISTRATION, METRONOMIC; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RANDOM ALLOCATION; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901413559     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.04.002     Document Type: Article

References (40)

1. Chen W., Zheng R., Zhang S., Zhao P., Li G., Wu L., He J. Report of incidence and mortality in China cancer registries. Chin. J. Cancer Res. 2009, 25(2013):10-21.
2. Moriwaki T., Bando H., Takashima A., Yamazaki K., Esaki T., Yamashita K., Fukunaga M., Miyake Y., Katsumata K., Kato S., Satoh T., Ozeki M., Baba E., Yoshida S., Boku N., Hyodo I. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med. Oncol. 2012, 29:2842-2848.
3. Buzdar A.U., Suman V.J., Meric-Bernstam F., Leitch A.M., Ellis M.J., Boughey J.C., Unzeitig G., Royce M., McCall L.M., Ewer M.S., Hunt K.K. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013, 14:1317-1325.
4. Martin M., Rodriguez-Lescure A., Ruiz A., Alba E., Calvo L., Ruiz-Borrego M., Munarriz B., Rodriguez C.A., Crespo C., Alava E., Lopez Garcia-Asenjo J.A., Guitian M.D., Almenar S., Gonzalez-Palacios J.F., Vera F., Palacios J., Ramos M., Gracia Marco J.M., Lluch A., Alvarez I., Segui M.A., Mayordomo J.I., Anton A., Baena J.M., Plazaola A., Modolell A., Pelegri A., Mel J.R., Aranda E., Adrover E., De Alvarez J.V., Garcia Puche J.L., Sanchez-Rovira P., Gonzalez S., Lopez-Vega J.M. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J. Natl. Cancer Inst. 2008, 100:805-814.
5. Yalcin S., Uslu R., Dane F., Yilmaz U., Zengin N., Buyukunal E., Buyukberber S., Camci C., Sencan O., Kilickap S. Bevacizumab+ Capecitabine as maintenance therapy after initial Bevacizumab+ XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'stop and go'study results-a turkish oncology group trial. Oncology 2013, 85:328-335.
6. Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63:4342-4346.
7. Tournigand C., Cervantes A., Figer A., Lledo G., Flesch M., Buyse M., Mineur L., Carola E., Etienne P.L., Rivera F., Chirivella I., Perez-Staub N., Louvet C., Andre T., Tabah-Fisch I., de Gramont A. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study. J. Clin. Oncol. 2006, 24:394-400.
8. Patel J.D., Socinski M.A., Garon E.B., Reynolds C.H., Spigel D.R., Olsen M.R., Hermann R.C., Jotte R.M., Beck T., Richards D.A., Guba S.C., Liu J., Frimodt-Moller B., John W.J., Obasaju C.K., Pennella E.J., Bonomi P., Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2013, 31:4349-4357.
9. Koopman M., Antonini N.F., Douma J., Wals J., Honkoop A.H., Erdkamp F.L., de Jong R.S., Rodenburg C.J., Vreugdenhil G., Loosveld O.J., van Bochove A., Sinnige H.A., Creemers G.J., Tesselaar M.E., Slee P.H., Werter M.J., Mol L., Dalesio O., Punt C.J. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370:135-142.
10. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000, 105:1045-1047.
11. Kerbel R.S., Klement G., Pritchard K.I., Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol. 2002, 13:12-15.
12. Colleoni M., Rocca A., Sandri M.T., Zorzino L., Masci G., Nole F., Peruzzotti G., Robertson C., Orlando L., Cinieri S., de B.F., Viale G., Goldhirsch A. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 2002, 13:73-80.
13. Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 2008, 68:4500-4505.
14. Kamat A.A., Kim T.J., Landen C.N., Lu C., Han L.Y., Lin Y.G., Merritt W.M., Thaker P.H., Gershenson D.M., Bischoff F.Z., Heymach J.V., Jaffe R.B., Coleman R.L., Sood A.K. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007, 67:281-288.
15. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4:423-436.
16. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., Shaked Y., Mancuso P., Goldhirsch A., Rocca A., Pietri E., Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 2008, 26:4899-4905.
17. Gebbia V., Serretta V., Borsellino N., Valerio M.R. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel. Urology 2011, 78:1125-1130.
18. Kolinsky K., Shen B.Q., Zhang Y.E., Kohles J., Dugan U., Zioncheck T.F., Heimbrook D., Packman K., Higgins B. In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. Mol. Cancer Ther. 2009, 8:75-82.
19. Patten S.G., Adamcic U., Lacombe K., Minhas K., Skowronski K., Coomber B.L. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment. BMC Cancer 2010, 10:683.
20. Manu K.A., Shanmugam M.K., Ramachandran L., Li F., Fong C.W., Kumar A.P., Tan P., Sethi G. First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kappaB pathway. Clin. Cancer Res. 2012, 18:2220-2229.
21. Lin P.C., Chen W.S., Chao T.C., Yang S.H., Tiu C.M., Liu J.H. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother. Pharmacol. 2007, 60:351-356.
22. Ogata Y., Tanaka T., Akagi Y., Ishibashi N., Tsuji Y., Matono K., Isobe M., Sueyoshi S., Kaibara A., Shirouzu K. Multicenter phase II study of a new effective S-1 and irinotecan combination schedule in patients with unresectable metastatic or recurrent colorectal cancer. Clin. Med. Insights Oncol. 2013, 7:21-30.
23. Allegrini G., Falcone A., Fioravanti A., Barletta M.T., Orlandi P., Loupakis F., Cerri E., Masi G., Di Paolo A., Kerbel R.S., Danesi R., Del Tacca M., Bocci G. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 2008, 98:1312-1319.
24. Hackl C., Man S., Francia G., Milsom C., Xu P., Kerbel R.S. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2013, 62:259-271.
25. Fedele P., Marino A., Orlando L., Schiavone P., Nacci A., Sponziello F., Rizzo P., Calvani N., Mazzoni E., Cinefra M., Cinieri S. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur. J. Cancer 2012, 48:24-29.
26. Wu H., Xin Y., Xu C., Xiao Y. Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Exp. Ther. Med. 2012, 3:650-654.
27. Naganuma Y., Choijamts B., Shirota K., Nakajima K., Ogata S., Miyamoto S., Kawarabayashi T., Emoto M. Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci. 2011, 102:1545-1552.
28. Ng S.S., Sparreboom A., Shaked Y., Lee C., Man S., Desai N., Soon-Shiong P., Figg W.D., Kerbel R.S. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin. Cancer Res. 2006, 12:4331-4338.
29. Calleri A., Bono A., Bagnardi V., Quarna J., Mancuso P., Rabascio C., Dellapasqua S., Campagnoli E., Shaked Y., Goldhirsch A., Colleoni M., Bertolini F. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin. Cancer Res. 2009, 15:7652-7657.
30. Mainetti L.E., Rico M.J., Fernandez-Zenobi M.V., Perroud H.A., Roggero E.A., Rozados V.R., Scharovsky O.G. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. Ann. Oncol. 2013, 24:2310-2316.
31. Bocci G., Fioravanti A., Orlandi P., Di Desidero T., Natale G., Fanelli G., Viacava P., Naccarato A.G., Francia G., Danesi R. Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1. Neoplasia 2012, 14:833-845.
32. Perroud H.A., Rico M.J., Alasino C.M., Pezzotto S.M., Rozados V.R., Scharovsky O.G. Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer. Indian J. Cancer 2013, 50:115-121.
33. Albertsson P., Lennernas B., Norrby K. Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 2012, 120:147-156.
34. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., Kerbel R.S. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006, 66:3386-3391.
35. Francia G., Shaked Y., Hashimoto K., Sun J., Yin M., Cesta C., Xu P., Man S., Hackl C., Stewart J., Uhlik M., Dantzig A.H., Foster F.S., Kerbel R.S. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol. Cancer Ther. 2012, 11:680-689.
36. Gunningham S.P., Currie M.J., Morrin H.R., Tan E.Y., Turley H., Dachs G.U., Watson A.I., Frampton C., Robinson B.A., Fox S.B. The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. J. Pathol. 2007, 212:335-344.
37. Garmy-Susini B., Varner J.A. Circulating endothelial progenitor cells. Br. J. Cancer 2005, 93:855-858.
38. Jimenez B., Volpert O.V., Crawford S.E., Febbraio M., Silverstein R.L., Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. 2000, 6:41-48.
39. Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T., Rawn K., Voskas D., Dumont D.J., Ben-David Y., Lawler J., Henkin J., Huber J., Hicklin D.J., D'Amato R.J., Kerbel R.S. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7:101-111.
40. Sun D., Ma Y., Han H., Yin Z., Liu C., Feng J., Zhou X., Li X., Xiao A., Yu R. Thrombospondin-1 short hairpin RNA suppresses tubulointerstitial fibrosis in the kidney of ureteral obstruction by ameliorating peritubular capillary injury. Kidney Blood Press. Res. 2012, 35:35-47.